DexCom, Inc.  

(Public, NASDAQ:DXCM)   Watch this stock  
Find more results for DXCM
+0.63 (1.11%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 56.36 - 57.78
52 week 42.62 - 86.32
Open 56.79
Vol / Avg. 0.00/1.18M
Mkt cap 4.98B
P/E     -
Div/yield     -
EPS -0.57
Shares 86.90M
Beta 0.21
Inst. own 122%
Mar 13, 2018
DexCom Inc at Barclays Global Healthcare Conference - 2:35PM EDT - Add to calendar
Mar 5, 2018
DexCom Inc at Raymond James Institutional Investors Conference - 8:40AM EST - Add to calendar
Feb 27, 2018
Q4 2017 DexCom Inc Earnings Call - 4:30PM EST - Add to calendar
Feb 27, 2018
Q4 2017 DexCom Inc Earnings Release - 4:00PM EST - Add to calendar
Jan 9, 2018
DexCom Inc at JPMorgan Healthcare Conference - Webcast
Jan 8, 2018
Preliminary Q4 2017 DexCom Inc Earnings Release
Dec 14, 2017
DexCom Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference - Webcast
Nov 29, 2017
DexCom Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1.08% -11.44%
Operating margin -0.27% -11.15%
EBITD margin - -8.51%
Return on average assets -0.98% -18.88%
Return on average equity -2.17% -25.98%
Employees 1,900 -
CDP Score - -


6340 Sequence Dr
SAN DIEGO, CA 92121-4356
United States - Map
+1-858-2000200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Officers and directors

Terrance H. Gregg Executive Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Kevin R. Sayer President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Quentin S. Blackford Chief Financial Officer
Age: 38
Bio & Compensation  - Reuters
Donald Abbey Executive Vice President, Quality and Information Technology
Age: 50
Bio & Compensation  - Reuters
Andrew K. Balo Executive Vice President - Clinical, Regulatory and Quality
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard B. Doubleday Executive Vice President, Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Steven R. Pacelli Executive Vice President - Strategy and Corporate Development
Age: 45
Bio & Compensation  - Reuters
Heather Ace Senior Vice President, Human Resources
Age: 47
Bio & Compensation  - Reuters
Jake Leach Senior Vice President of Research and Development
Age: 39
Bio & Compensation  - Reuters
Jeffrey C. Moy Senior Vice President - Operations
Age: 56
Bio & Compensation  - Reuters